DEF6

Across TCGA pan-cancer cohorts, DEF6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DEF6 data layer compared with 28 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher DEF6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DEF6 expression acts as an unfavorable survival marker.

UCS, ESCA, and LUAD are the cancer types where DEF6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	All	0.068	0.524	<.001	48	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
LUAD	OS	Median	II,III,IV	0.079	0.677	<.001	6	view →
PRAD	DFS	Median	All	0.545	0.935	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DEF6–UCS (DFS)

Open the UCS breakdown →